Clinical development, biometrics and drug registration

Debioclinic is the clinical research unit of Debiopharm Group, a global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medial needs.

Debioclinic provides regulatory, biometric, pharmaceutical, clinical and project management support to Debiopharm Group relaying on preferred providers partnerships with contract research organisations (CROs) and other healthcare professional providers.

Milestones

In 15 years, Debioclinic has conducted 80 clinical trials (phase I to III) in 20 countries involving more than 6000 patients.

Management

Silvano Brienza Chief Executive Officer - Scientific Director, Debioclinic S. A.

Dr. Brienza received his Italian Medical Degree in 1983 from the University “La Sapienza” of Rome and obtained a French certificate in Oncology in 1992. He has more than 15 years experience in clinical research, initiated first in the hospital as an oncologist and continued in the industry as responsible, at various degrees, for the development of anticancer drugs. He extended his clinical experience at the Paul Brousse Hospital in Villejuif, France as assistant oncologist. He joined Debioclinic S.A. in 1992. He is in charge of the Oxaliplatin program and obtained, with his clinical research team, the first approval of this drug in 1996.